Venclexta and Praluent drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Venclexta (venetoclax) and Praluent (alirocumab). Common drug interactions include death among females and neutropenia among males.

The phase IV clinical study analyzes what interactions people have when they take Venclexta and Praluent. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Venclexta?

Venclexta has active ingredients of venetoclax. eHealthMe is studying from 31,425 Venclexta users. Check the latest studies of Venclexta.

What is Praluent?

Praluent has active ingredients of alirocumab. It is often used in high blood cholesterol. eHealthMe is studying from 24,963 Praluent users. Check the latest studies of Praluent.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

13 people who take Venclexta and Praluent together, and have interactions are studied.

Venclexta and Praluent drug interactions.

What are the common drug interactions of Venclexta and Praluent, by gender? *:

female:

Death

male:

Neutropenia (an abnormally low number of neutrophils)
Diarrhoea
Dizziness
Gout (uric acid crystals building up in the body)
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
Leukopenia (less number of white blood cells in blood)
Muscular weakness (muscle weakness)
Tumour lysis syndrome (a group of metabolic complications that can occur after treatment of cancer, these complications are caused by the breakdown products of dying cancer cells)
Viral infection
Weight decreased

What are the common drug interactions of Venclexta and Praluent, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Death

60+:

Neutropenia (an abnormally low number of neutrophils)
Diarrhoea
Dizziness
Gout (uric acid crystals building up in the body)
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
Leukopenia (less number of white blood cells in blood)
Muscular weakness (muscle weakness)
Tumour lysis syndrome (a group of metabolic complications that can occur after treatment of cancer, these complications are caused by the breakdown products of dying cancer cells)
Viral infection
Weight decreased

What are the existing conditions these people have? *

Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 7 people, 53.85%
High Blood Pressure: 5 people, 38.46%
Heart Disease: 4 people, 30.77%
Hyperlipidaemia (presence of excess lipids in the blood): 4 people, 30.77%
Herpes Zoster: 4 people, 30.77%
Cardiac Disorder: 4 people, 30.77%
Stress And Anxiety: 4 people, 30.77%
Pain: 3 people, 23.08%
Cough: 3 people, 23.08%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 3 people, 23.08%

* Approximation only. Some reports may have incomplete information.

Do you take Venclexta and Praluent?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously